×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KPTI – karyopharm therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KPTI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/18
08:13 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
2/12
02:23 pm
kpti
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
2/12
07:54 am
kpti
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/12
07:30 am
kpti
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
High
Report
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2/5
07:30 am
kpti
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Low
Report
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
2/5
07:00 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
2/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
07:00 am
kpti
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Medium
Report
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
07:30 am
kpti
karyopharm therapeutics inc.
MISS
Report
27.6%
karyopharm therapeutics inc.
11/3/2025
07:00 am
kpti
karyopharm therapeutics inc.
MISS
Report
1.3%
karyopharm therapeutics inc.
8/11/2025
07:30 am
kpti
karyopharm therapeutics inc.
MISS
Report
-5.8%
karyopharm therapeutics inc.
5/12/2025
04:05 pm
kpti
karyopharm therapeutics inc.
BEAT
Report
-20.0%
karyopharm therapeutics inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/19
04:06 pm
kpti
Form 8-K Karyopharm Therapeutics For: Feb 18
Neutral
Report
Form 8-K Karyopharm Therapeutics For: Feb 18
2/19
04:02 pm
kpti
Form 4 Karyopharm Therapeutics For: Feb 17 Filed by: Poulton Stuart
Low
Report
Form 4 Karyopharm Therapeutics For: Feb 17 Filed by: Poulton Stuart
2/17
10:29 am
kpti
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.
2/13
06:04 am
kpti
Form 10-K Karyopharm Therapeutics For: Dec 31
Medium
Report
Form 10-K Karyopharm Therapeutics For: Dec 31
2/12
09:04 am
kpti
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
High
Report
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
2/12
07:32 am
kpti
Form 8-K Karyopharm Therapeutics For: Feb 12
High
Report
Form 8-K Karyopharm Therapeutics For: Feb 12
2/10
04:49 pm
kpti
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC
High
Report
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC
2/9
04:12 pm
kpti
Form 4 Karyopharm Therapeutics For: Feb 05 Filed by: Paulson Richard A.
Medium
Report
Form 4 Karyopharm Therapeutics For: Feb 05 Filed by: Paulson Richard A.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Form 3 Karyopharm Therapeutics For: Feb 26 Filed by: Paulson Richard A.
70.1%
9/16 Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million 10.7%
3/3 Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock 9.8%
5/15 Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award 8.6%
10/9 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%
1/8 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $21.00 price target on the stock. 7.2%
11/1 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 7.2%
4/20 Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 7.1%
11/4 Karyopharm Therapeutics Inc (KPTI) Q3 2019 Earnings Call Transcript [The Motley Fool] 6.9%
7/30 Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019 6.9%
9/16 Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million 10.7%
3/3 Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock 9.8%
5/15 Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award 8.6%
10/9 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%
1/8 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $21.00 price target on the stock. 7.2%
11/1 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 7.2%
4/20 Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 7.1%
11/4 Karyopharm Therapeutics Inc (KPTI) Q3 2019 Earnings Call Transcript [The Motley Fool] 6.9%
7/30 Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019 6.9%
TOP News Decliners
3/13
Form S-8 Karyopharm Therapeutics
-13.2%
3/12 Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer -13.1%
3/6 Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares -13.0%
7/5 Karyopharm Therapeutics Inc (NASDAQ: KPTI) had its price target raised by analysts at HC Wainwright from $29.00 to $32.00. They now have a "buy" rating on the stock. -11.5%
3/2 Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock -9.8%
1/17 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.5%
8/1 Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. -9.4%
3/5 Karyopharm Therapeutics: All Systems Go [Seeking Alpha] -9.0%
7/10 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. -8.4%
3/17 Form 3 Karyopharm Therapeutics For: Mar 16 Filed by: DEMAREE JOHN -8.3%
3/12 Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer -13.1%
3/6 Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares -13.0%
7/5 Karyopharm Therapeutics Inc (NASDAQ: KPTI) had its price target raised by analysts at HC Wainwright from $29.00 to $32.00. They now have a "buy" rating on the stock. -11.5%
3/2 Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock -9.8%
1/17 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.5%
8/1 Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. -9.4%
3/5 Karyopharm Therapeutics: All Systems Go [Seeking Alpha] -9.0%
7/10 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. -8.4%
3/17 Form 3 Karyopharm Therapeutics For: Mar 16 Filed by: DEMAREE JOHN -8.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: